Universidad de Salamanca-ko ikertzaileekin lankidetzan egindako argitalpenak (13)

2023

  1. Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer

    Nature Communications, Vol. 14, Núm. 1

2017

  1. Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer

    Molecular Cancer Therapeutics, Vol. 16, Núm. 11, pp. 2552-2562

  2. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors

    Oncotarget, Vol. 8, Núm. 12, pp. 19478-19490

2013

  1. Edelfosine lipid nanosystems overcome drug resistance in leukemic cell lines

    Cancer Letters, Vol. 334, Núm. 2, pp. 302-310

2012

  1. Complete inhibition of extranodal dissemination of lymphoma by edelfosine-loaded lipid nanoparticles

    Nanomedicine, Vol. 7, Núm. 5, pp. 679-690

2011

  1. Further characterization of the electrogenicity and ph sensitivity of the human organic anion-transporting polypeptides OATP1B1 and OATP1B3

    Molecular Pharmacology, Vol. 79, Núm. 3, pp. 596-607

  2. In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma

    Journal of Controlled Release, Vol. 156, Núm. 3, pp. 421-426

2010

  1. In vitro and in vivo selective antitumor activity of edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts

    Clinical Cancer Research, Vol. 16, Núm. 7, pp. 2046-2054

  2. Lipid raft-targeted therapy in multiple myeloma

    Oncogene, Vol. 29, Núm. 26, pp. 3748-3757

2009

  1. Comparative study of A HPLC-MS assay versus an UHPLC-MS/MS for anti-tumoral alkyl lysophospholipid edelfosine determination in both biological samples and in lipid nanoparticulate systems

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 877, Núm. 31, pp. 4035-4041

2008

  1. Lipid nanoparticles for alkyl lysophospholipid edelfosine encapsulation: Development and in vitro characterization

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 68, Núm. 2, pp. 207-213

  2. Recomendaciones para la monitorización de antibióticos en pacientes críticos ingresados en UCI

    Enfermedades Infecciosas y Microbiologia Clinica

2004

  1. Quantitative determination of the antitumor alkyl ether phospholipid edelfosine by reversed-phase liquid chromatography-electrospray mass spectrometry: Application to cell uptake studies and characterization of drug delivery systems

    Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 810, Núm. 1, pp. 85-92